With the additional funding, Sera aims to develop new tests for predicting the risk of preterm birth in women in developing countries, the company said.
The agreement gives Caprion, which did significant development work on the test, exclusive rights to market and commercialize Xpresys Lung inCanada.
The 141-sample study found the test could identify benign lesions in lung cancer patients with a negative predictive value of between 84 percent and 98 percent.
The approach, commonly used for genomics research, could prove effective for shotgun proteomics, as well, according to a paper byErasmusUniversityresearchers.
The company this year will start clinical studies for the four-protein panel in central Europe, theUK, and theUS, enrolling a total of 1,500 patients.
The instruments will be housed at the new Metabolomics Technology Demonstration Centre and will help firms translate biomarkers into clinical tests.
The company has no plans to position NephroCheck for long-term prognosis but said the findings bolster data supporting use of the test in the acute setting.
The firm is validating the test and expects results to be available in the second quarter of 2015 with commercial launch of the test following around mid-year.
The funding follows a $19.3 million Series A round Sera closed in 2011 and will support development of its proteomic test for assessing women's risk of preterm delivery.
From research collaborations to corporate acquisitions, attention from the broader scientific community highlighted the field's capabilities and limitations.
Caprion will use its discovery and targeted mass spec platforms to analyze roughly 400 samples from the UK Collaborative Trial for Ovarian Cancer Screening.
Investors have agreed to purchase approximately $10.5 million of shares of common stock as well as warrants to purchase up to $8.4 million in additional shares.
The marker has the potential to improve upon existing markers like HER2 and HR status while also expanding the population of patients considered for neratinib treatment.
The company said that it plans to use the funds to complete and commercialize in vitro diagnostic tests for rheumatoid arthritis, systemic lupus, and systemic sclerosis.
Since launching it in June, the firm has sold roughly 1,000 tests. It measures eight proteins to determine the likelihood that a patient's cancer is aggressive.
The tests use the company's Nanotrap reagents, hydrogel nanoparticles functionalized with internal affinity baits to enrich target analytes for downstream analysis.
The funds will support work to evaluate the effectiveness of the company's immunosignature technology in the diagnosis of brain cancer.
The company has failed to meet the minimum $2.5 million in stockholders' equity required for listing on the exchange.
Point-of-care testing, automation, and panelization of nucleic acid amplification testing are the future of the clinical lab ― and will likely change how labs and clinicians relate.
The firm seeks to raise between A$4 million and A$6 million through an offering of up to 30 million shares of its stock at A$.20 per share.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.